<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-12-28">December 28, 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Christoph</forename><surname>Treese</surname></persName>
							<email>christoph.treese@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Gastroenterology, Infectious Diseases and Rheumatology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">Berlin Institute of Health (BIH)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pedro</forename><surname>Sanchez</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Gastroenterology, Infectious Diseases and Rheumatology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patricia</forename><surname>Grabowski</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Gastroenterology, Infectious Diseases and Rheumatology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Department of Gastroenterology and Endocrinology</orgName>
								<orgName type="institution">Zentralklinik Bad Berka GmbH</orgName>
								<address>
									<settlement>Bad Berka</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Erika</forename><surname>Berg</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute for Pathology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hendrik</forename><surname>Bla ¨ker</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute for Pathology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Martin</forename><surname>Kruschewski</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of General, Visceral and Thoracic Surgery</orgName>
								<orgName type="institution">Sta ¨dtisches Klinikum Solingen GmbH</orgName>
								<address>
									<settlement>Solingen, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oliver</forename><surname>Haase</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Department of General, Visceral, Vascular and Thoracic Surgery</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Mitte</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Hummel</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Institute for Pathology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Severin</forename><surname>Daum</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Gastroenterology, Infectious Diseases and Rheumatology</orgName>
								<orgName type="institution">Charite ´University Medicine Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Berlin, Germany</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Ps</surname></persName>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="institution">University School of Medicine</orgName>
								<address>
									<country key="CN">CHINA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-12-28">December 28, 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">5E23D63B9CD6EAD112E1FC242D636886</idno>
					<idno type="DOI">10.1371/journal.pone.0168237</idno>
					<note type="submission">Received: June 20, 2016 Accepted: November 28, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>CT MH SD</term>
					<term>Data curation: CT PS EB CT EB MH SD</term>
					<term>Software: CT</term>
					<term>Supervision: SD MH HB PS EB HB MH</term>
					<term>Visualization: CT</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background 5-year survival rate in patients with early adenocarcinoma of the gastro-esophageal junction or stomach (AGE/S) in Caucasian patients is reported to be 60-80%.</s><s>We aimed to identify prognostic markers for patients with UICC-I without lymph-node involvement (N0).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>Clinical data and tissue specimen from patients with AGE/S stage UICC-I-N0, treated by surgery only, were collected retrospectively.</s><s>Tumor size, lymphatic vessel or vein invasion, grading, classification systems (WHO, Lauren, Ming), expression of BAX, BCL-2, CDX2, Cyclin E, E-cadherin, Ki-67, TP53, TP21, SHH, Survivin, HIF1A, TROP2 and mismatch repair deficiency were analyzed using tissue microarrays and correlated with overall and tumor related survival.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>129 patients (48 female) with a mean follow-up of 129.1 months were identified.</s><s>5-year overall survival was 83.9%, 5-year tumor related survival was 95.1%.</s></p><p><s>Poorly differentiated medullary cancer subtypes (p&lt;0.001) and positive vein invasion (p&lt;0.001) were identified as risk factors for decreased overall-and tumor related survival.</s><s>Ki-67 (p = 0.012) and TP53 mutation (p = 0.044) were the only immunohistochemical markers associated with worse overall survival but did not reach significance for decreased tumor related survival.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Adenocarcinoma of the esophago-gastric junction and stomach (AEG/S) is the fourth most common cancer worldwide in men and the fifth most common cancer diagnosis in women <ref type="bibr" target="#b0">[1]</ref>.</s><s>The prognosis of patients with AEG/S is poor, making it the second leading cause of cancer death worldwide <ref type="bibr" target="#b0">[1]</ref>.</s></p><p><s>Complete resection (R0) is considered the treatment of choice with curative intent, yet, in up to 40% of patients tumor recurrence occurs even after R0 resection <ref type="bibr" target="#b1">[2]</ref>.</s><s>An extended D2 lymphadenectomy as surgical procedure is well established, confirming the role of lymphatic invasion in this cancer entity <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b3">4]</ref>.</s><s>Approximately 30% of patients with AEG/S exhibit stage UICC I at time of diagnosis <ref type="bibr" target="#b4">[5]</ref> and despite early tumor-stage and radical tumor resection, this group of patients has a 5-year overall survival rate of only 60%-80% <ref type="bibr" target="#b5">[6,</ref><ref type="bibr" target="#b6">7]</ref>.</s><s>In these studies lymph node involvement was the main risk factor for tumor relapse.</s><s>Due to higher incidence of this cancer type in East Asia, most studies on prognosis and survival describe patients from Japan and China.</s><s>Solely Borie et al. <ref type="bibr" target="#b7">[8]</ref> studied the survival of Caucasian patients stage UICC I stratified according to lymph node involvement and demonstrated a tumor related five year survival of 92% in patients without lymph node involvement.</s></p><p><s>In the search for additional and refined prognostic risk factors in advanced tumor stages, several studies analyzed histomorphological criteria like tumor size, lymphatic vessel invasion, vein invasion, grading, Lauren classification, WHO classification, and MING classification <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>.</s><s>Several studies described molecular markers considered predictive for survival of which we selected for immunohistochemical evaluation and categorized in subgroups: markers for proliferation (Ki-67 <ref type="bibr" target="#b14">[15]</ref>), cell cycle regulation (Cyclin E <ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref>, p21 <ref type="bibr" target="#b18">[19]</ref>, TP53 <ref type="bibr" target="#b19">[20]</ref>), apoptosis (BAX <ref type="bibr" target="#b20">[21]</ref>, BCL <ref type="bibr" target="#b21">[22]</ref>, Survivin <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref>), cell adhesion (E-cadherin <ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref>), cell differentiation (CDX2) <ref type="bibr" target="#b28">[29]</ref>, SHH (Sonic hedgehog) <ref type="bibr" target="#b29">[30]</ref>, TROP2 <ref type="bibr" target="#b30">[31]</ref>, HIF1A (hypoxia induced factor 1α) <ref type="bibr" target="#b31">[32]</ref> and mismatch repair deficiency <ref type="bibr" target="#b32">[33]</ref>.</s></p><p><s>These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without the main confounder lymph node involvement in order to refine the identification of patients at high-risk.</s></p><p><s>To this end we conducted this retrospective study with the aim to identify prognostic histopathological and immunohistochemical markers using tissue microarrays (TMAs) from patients with AEG/S stage UICC I-N0 and correlated these data with overall survival and tumor related survival.</s><s>Refined biomarkers in this subgroup might not only be predictive for survival, but might guide treatment to improve survival in high-risk patients by possibly intensifying treatment by adjuvant chemotherapy or chemoradiotherapy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients</head><p><s>Clinical data from patients with AEG/S stage pT1 and pT2 pN0M0, treated solely by surgery between September 1993 and May 2010 at Charité-University Medicine Berlin, were collected retrospectively.</s></p><p><s>The data including patient characteristics and follow-up information were retrieved from the patient management software (SAP1) and the regional population-based cancer registry (Gemeinsames Krebsregister).</s><s>This study was approved by the Institutional Ethical Review Board of the Charité (EA4/115/10).</s></p><p><s>All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.</s><s>No patient consent was necessary since this was a retrospective study.</s><s>Patients' records were collected and anonymized, de-identified before the analysis.</s></p><p><s>Patients without recurrent disease were followed-up for a minimum period of 24 months.</s><s>Overall survival, used as a measure of prognosis, was defined as time from diagnosis to death or last follow-up.</s><s>Tumor related survival was defined as time from diagnosis to tumor related death or last follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Tissue Samples</head><p><s>Tissue samples were collected from the pathological archive of the Charité-University Medicine Berlin.</s><s>From 129 surgically treated patients 80 paraffin embedded tumor samples were available.</s><s>A specialist in gastrointestinal pathology (H.B.) reanalyzed and reconfirmed the primary postoperative histological diagnosis and tumor stage and classified the histological architecture of gastric carcinoma using Lauren's, Ming and WHO classification <ref type="bibr" target="#b33">[34]</ref>.</s><s>According to the WHO classification for colon and rectum carcinoma we added the subtype of medullary tumors to our analysis <ref type="bibr" target="#b33">[34]</ref><ref type="bibr" target="#b34">[35]</ref><ref type="bibr" target="#b35">[36]</ref>.</s><s>We defined the poorly differentiated medullary cancer (PMC) subtype in congruence with Adachi et al. as a tumor characterized by sheets of monomorphic malignant cells showing solid growth and absence of glandular growth <ref type="bibr" target="#b34">[35]</ref>.</s><s>Tumor cells show only little pleomorphism, have round to oval, large nuclei and a high nuclear to cytoplasmic ratio, morphologically resembling medullary type colorectal cancer.</s><s>The PMCs did not show a deficiency of the mismatch repair system, as tested by immunohistochemistry.</s></p><p><s>Additional data concerning tumor size, depth of invasion, and tumor invasion of veins or lymphatic vessels were extracted from the Charité-University Medicine patient management software.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TMA and Immunohistochemistry</head><p><s>Tissue samples were screened in a HE-stained section for representative areas of solid tumors.</s><s>Two 1 mm-diameter tissue cores were punched out from each of the 80 available cases and were transferred to a recipient paraffin block.</s><s>Tissue from a tonsil was used as positive staining control and was also transferred to the same paraffin block.</s><s>After re-melting, sections (4 μmthick) were consecutively cut from each tissue microarray block.</s><s>HE staining was performed on TMA sections for confirmation of tumor and non-tumor tissue.</s></p><p><s>Immunohistochemical analysis was performed on TMA sections using monoclonal antibodies.</s><s>For pre-treatment a target retrieval solution (TRS) (HIF1A) or citrate buffer (pH = 6.0, 0.1M) was used.</s><s>Antibody binding was visualized using an APAAP-Kit (K5000 Dako1) for Ecadherin (1:50, clone 36B5, Novocastra1), Ki67 ) and a biotin labeled anti-goat IgG Antibody (Dako E0466) for TROP2 (1:100, clone P09758, R&amp;D Systems1).</s><s>For the mismatch-repair proteins immunohistochemistry was performed on an automated staining system (BenchMark Ultra, Roche Ventana, Germany) using prediluted antibodies (all Roche Ventana) MLH1 (clone M1), PMS2 (clone EPR3947), MSH2 (clone G219-1129), and MSH6 (clone 44) following the manufacturer's instructions.</s></p><p><s>Membrane, cytoplasmatic and nuclear stained cells with E-Cadherin, BCL2, HIF1A, BAX, SSH and solely nuclear stained cells with Cyclin E, TP21, CDX2 were scored according to the intensity of staining (0, none to weak; 1 = weak; 2 = moderate; 3 = strong) and the percentage of tumor cells stained (0 = 0% positive; 1 = 1-25% positive, 2 = 26-50% positive; 3 = 51-75% positive and 4, &gt; 75% positive).</s><s>Tumor samples with a score higher than 3 were evaluated as positive cases.</s></p><p><s>Concerning Ki-67, tumors with a proliferation rate higher than 20% were regarded as highly proliferative tumors.</s><s>For Survivin, all tumors with more than 5 percent positively stained cell nuclei were scored as Survivin positive samples <ref type="bibr" target="#b36">[37]</ref>.</s><s>A high number (75-100%) of TP53 positive stained cells with a strong nuclear staining intensity or tumors with no TP53 positive cells was used as a surrogate parameter for TP53 mutated samples <ref type="bibr" target="#b37">[38,</ref><ref type="bibr" target="#b38">39]</ref>.</s></p><p><s>Mismatch repair deficiency was scored, when a tumor showed specific loss of nuclear staining for at least one of the markers (MLH, PMS2, MSH2, MSH6)</s></p><p><s>The count of CD3 positive cells was performed in 4 representative regions of the tumor.</s><s>The average of counted cells was normalized in 0.1mm 2 of tumor area.</s></p><p><s>Each core was blindly scored by two independent evaluators (C.T. and S. D.) and reviewed by one pathologist (H.B.) and one biologist highly experienced in pathohistology (M.H.) and reconciled after intensive discussion.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p><s>Quantitative values are expressed as mean± standard deviation, median, and range, and categorical values with absolute and relative frequencies (count and percent).</s><s>Overall survival was evaluated in months from time of diagnosis until death or until the most recent follow-up using the Kaplan-Meier plots.</s><s>Differences in the survival curves were evaluated by the logrank test for significance.</s><s>The X 2 -test was used for comparison of frequencies.</s><s>A pvalue &lt; 0.05 was considered as statistically significant.</s><s>IBM SPSS Version 21 (Ehningen, Germany) was used for statistical analysis.</s></p><p><s>Reporting recommendations for tumor marker prognostic studies (REMARK) were applied for this study whenever applicable <ref type="bibr" target="#b39">[40]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Characteristics of Patients</head><p><s>Data of 129 patients (female = 48, age 29-90 years, median age 62.9 years) were retrieved for this study (see Table <ref type="table" target="#tab_0">1</ref>).</s><s>The cohort consisted of 96 patients with gastric cancer (2 pts.</s><s>upper third, 26 middle third, 55 lower third, 8 couplet stomach and 5 with no specified position in the stomach) and 33 patients with carcinoma of the gastroesophageal junction.</s><s>A D2 lymph node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two patients had only a D1 dissection and in one patient lymph node dissection status was not reported.)</s></p><p><s>The mean follow-up was 129.1 months and 21 patients (16.3%) died during the follow-up period, but only nine patients (7%) died from recurrence of AEG/S.</s></p><p><s>The 5-year overall survival of our population was 83.9%, the 5-year tumor related survival was 95.1% (Fig <ref type="figure" target="#fig_1">1</ref>).</s><s>A relapse of AEG/S occurred in nine patients whereas 120 patients remained relapse-free in the observation period.</s><s>A stage pT1N0M0 was assigned to 68.2% of patients (88/129), and 31.8% of patients (41/129) were pT2N0M0.</s><s>In 80 cases the information of lymphatic vessel invasion was described and 14 (10.9%) were staged as L1 and 66 (51.2%) as L0.</s><s>In 71 cases the vein invasion level was documented.</s><s>Eight patients (6.2%) were staged as V1 and 63 (48.8%) as V0 (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Histopathological Characteristics</head><p><s>From 129 patients with clinical data, 80 formalin-fixed paraffin embedded tissue samples were available and reassessed (Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>The reevaluation by a specialist in GI pathology (H.B.) resulted in 31 (38.8%)</s><s>tumors staged as T1a, 26 (32.5%) as T1b and 23 (28.8%) as T2.</s><s>Seven (8.8%) tumors showed vein invasion and 14 (17.5%) a lymphatic vessel invasion, while seven (8.8%) patients had G1, 27 (33.8%)</s><s>G2, and 46 (57.5%)</s><s>G3 tumors.</s></p><p><s>The histopathological classification according to Lauren yielded 56 (70.0%) intestinal, 13 (16.3%)</s><s>diffuse and 11 (13.8%)</s><s>mixed type tumors.</s><s>The WHO Classification resulted in: 40 (50.0%)</s><s>tubular histology, 9 (11.3%)</s><s>medullary, 3 (3.8%)</s><s>papillary, 4 (5.0%)</s><s>pyloric gland type, 2 (2.5%) mucinous, 15 (18.8%) signet ring and 7 (8.8%)</s><s>mixed type tumors (medullar subtype see Fig <ref type="figure" target="#fig_2">2A and 2B</ref>).</s><s>Using the Ming classification, tumors were in 38 cases (47.5%) of the expansive and in 37 cases (46.3%) of the infiltrative type.</s><s>In five cases (6.3%) a definite classification was not possible (Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>The correlation of histopathological characteristics with tumor related survival or overall survival showed significant differences between the overall survival and tumor related survival for the V0 and V1 subpopulation (5-year tumor related survival V0 96.7%, V1 60.0% p&lt;0.001; 5-year overall survival V0 85.9%, V1 42.9% p = 0.001) (Table <ref type="table" target="#tab_1">2</ref>; Fig <ref type="figure" target="#fig_1">1</ref>).</s><s>Furthermore, we could identify significant differences between poorly differentiated medullary cancer (PMC) subtypes and non-PMC tumors (PMC vs. non-PMC: 5-year-overall survival 57.1% vs 87.8%; p = 0.007, 5-year tumor related survival 75.0%</s><s>vs 97.1%; p&lt;0.001) (Fig <ref type="figure" target="#fig_1">1</ref>).</s><s>Tumor grading, Lauren or Ming classification were no discriminating factors for survival (Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>A multivariate cox regression model was not reasonable as the number of our cases, especially of relapsed cases, did not meet the critical number proposed by Peducci et al <ref type="bibr" target="#b40">[41]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemistry</head><p><s>Although all cases were present in duplicate, between 12.5 to 20% (10-20) of the cases were not usable for analysis in the TMA.</s><s>Reasons for exclusion were cores with less than 10% tumor tissue.</s><s>In the analysis of the immunhistochemical markers BAX, BCL-2, CDX2, Cyclin E, E-Cadherin, Ki-67, TP53, TP21, SHH, Survivin, HIF1A, and TROP2 we could not find a significant correlation with marker expression and prognosis (see Table <ref type="table" target="#tab_3">3</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>.).</head><p><s>In a more detailed analysis for positive and negative markers we detected a lower 5-year overall survival for Ki-67 high proliferative tumors (high: 79.9% vs. low: 100% p = 0.012) and for tumors with TP53 surrogate mutation pattern (mut 66.3% vs. wt 92.5%; p = 0.044).</s><s>These markers showed a trend in the 5-year-tumor related survival analysis (Ki-67 high 90.2% vs.  <ref type="table" target="#tab_3">3</ref>.</s><s>Immunohistochemical biomarker analysis: All immunohistochemical markers except Ki-67, TP53, and Survivin were analyzed using the semiquantitative scoring system described in the method section.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pts. (%)</head><p><s>Tumor related survival (%) Overall survival (%) low 100% and TP53 mut: 85.2% vs wt 95.7%), but did not reach level of significance (Ki-67 p = 0.075 and TP53 p = 0.057).</s><s>The analysis of mismatch repair system deficiency and proficiency did not show any significant differences for overall survival or tumor related survival (5-year tumor related survival dMMR 100% vs. pMMR 92.1%, p = 0.461; 5-year overall survival dMMR 75.0%</s><s>vs pMMR 82.0%, p = 0.842) With regard to the above identified histomorphological risk factors (poorly differentiated medullary cancer subtype, venous invasion) we found in PMC significantly more T2 tumors (p = 0.034), more undifferentiated tumors (p = 0.024) and more p53 mutated tumors (p = 0.045).</s><s>None of the PMC showed a deficient MMR.</s></p><p><s>For detailed classification of the PMC we counted the CD3 positive lymphocyte per 0.1mm 2 tumor area.</s><s>We detected less CD3 positive cells in the PMC compared to non-PMC tumors (120.5 per 0.1mm 2 vs 212.3 per 0.1mm 2 ).</s><s>The difference did not reach level of significance (p = 0.1).</s></p><p><s>T2-stage was associated with positive venous invasion (p = 0.033) and p53 mutated subtype (p = 0.003).</s><s>Furthermore, we found a high correlation between V1 and L1 status (p&gt;0.0001).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>The aim of this retrospective study was to identify prognostic histopathological and immunohistological markers for patients with AEG/S stage UICC I on top of the known main risk factor lymph node metastasis to identify potential high risk subgroups.</s></p><p><s>Detailed clinical data were retrieved for 129 patients and histopathological data were assessable in 80 cases in this study.</s><s>This Caucasian UICCI/N0 patient cohort with FFPE samples is one of the largest of gastric cancer in Europe as the incidence is substantial lower and tumor stages are more advanced in comparison to Eastern Asia <ref type="bibr" target="#b41">[42,</ref><ref type="bibr" target="#b42">43]</ref>.</s></p><p><s>From 129 patients followed over 10 years we found 9 patients with tumor related death.</s><s>This high 5-year tumor-related overall survival of 95.1% proves the effectivity of surgical treatment in this early stage disease without lymph node involvement.</s><s>Similar favorable data are well known from Asian patients (97.8% 5-year tumor-related overall survival) <ref type="bibr" target="#b43">[44]</ref>.</s><s>Similar results in Caucasians were reported in a single study by Borie et al. with a 92% 5-year tumor- related overall survival <ref type="bibr" target="#b7">[8]</ref>.</s><s>The large German gastric cancer trial showed in about 250 patients recruited from 1986-1989 a 5-year overall survival depending on the number of resected lymph nodes from 81%-85% in T1N0 stages to 67% in T2N0 stages <ref type="bibr" target="#b5">[6]</ref>.</s><s>These differences in survival are probably attributable to increased surgical quality in the last decades and the decreased postoperative 30 day mortality rate (mean 30 day mortality rate of 0.8% in 18 trials between 1998-2014 <ref type="bibr" target="#b44">[45]</ref> compared to the German gastric cancer trial with 5.2% <ref type="bibr" target="#b2">[3]</ref>).</s></p><p><s>For the histopathological markers in our study, venous infiltration was a significant predictor for tumor related death in our patient group (5 year-tumor related survival V0 96.7%, V1 60.0% p = 0.005).</s><s>While these data are in accordance with Asian studies <ref type="bibr" target="#b9">[10,</ref><ref type="bibr" target="#b10">11]</ref>, we found a higher number of patients with poorly differentiated medullary cancer subtype, namely 11.3% (9/80) whereas the Asian data reported about 3.0% of PMC histology, defined as low differentiated lymphoepithelioma-like tumor type with a small amount of stromal tissue <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b35">36]</ref>.</s><s>Although definition of medullary subtype is still a point of discussion, our defining criteria are easily reproducible.</s><s>Similar to Asian patients, PMC subtype was associated with relapse and reduced prognosis in our patient population <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b35">36]</ref>.</s><s>Although PMC phenotype (see Fig 2A <ref type="figure" target="#fig_2">and 2B</ref>) is not part of the classification systems currently in use (WHO, Ming, Lauren), it seems to represent an atypical form of gastric cancer which should be studied further, considered as a separate entity, and included in histopathological classification systems <ref type="bibr" target="#b45">[46]</ref>.</s></p><p><s>According to our data, all other parameters analyzed, like Lauren and Ming classification, tumor size, grading, lymph vessel invasion, and signet ring cell type, did not show a prognostic relevance.</s><s>As other authors found grading, lymph vessel invasion and tumor size as prognostic in early tumor stages mainly with lymph node involvement <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref>, employing a more detailed analysis (N0 versus N+) of the tumor, might explain these differences.</s></p><p><s>The conclusion from our immunohistochemical data for prognostic biomarkers is somewhat limited by the rather small number of cases, solely 58-70 from 129 included patients could be analyzed, and the number of patients with tumor related death among this group amounts to six patients (see Table <ref type="table" target="#tab_3">3</ref>.).</s><s>A reduced overall survival for TP53 surrogate mutation pattern and for high proliferative (Ki-67&gt;20%) tumors could be demonstrated.</s><s>The identified histopathological risk factors vein invasion and PMC subtype were positively correlated with a TP53 mutation pattern.</s><s>TP53 and Ki-67 did not reach the level of significance in correlation with disease relapse in contrast to correlation with death by any cause.</s></p><p><s>Yet, the results for TP53-mutating pattern and high proliferating tumors are in concordance with other studies.</s><s>Over all stages of gastric cancer Ki-67 is associated with metastasis and disease progression in gastric cancer and is especially associated with lymph node involvement in early diseases <ref type="bibr" target="#b46">[47,</ref><ref type="bibr" target="#b47">48]</ref>.</s></p><p><s>Also TP53 mutation is known to be associated with reduced survival <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b48">49,</ref><ref type="bibr" target="#b49">50]</ref> and the mutation of TP53 plays a crucial role in the progression from intestinal metaplasia to gastric cancer <ref type="bibr" target="#b48">[49,</ref><ref type="bibr" target="#b50">51]</ref>.</s><s>Despite missing significance (p = 0.057) for this biomarker, the immunohistochemical TP53 surrogate mutation pattern seems to be a suitable molecular biomarker for early gastric cancer.</s></p><p><s>This retrospective study in a non-selected group of patients with early adenocarcinoma of the esophago-gastric junction and stomach corroborates older findings of a favorable prognosis in cases without lymph node involvement.</s><s>We could confirm the negative prognostic role of vein invasion in our population despite the small number of patients with relapse.</s><s>Furthermore, we could identify the subtype of poorly differentiated medullary cancer as a risk factor for disease recurrence in a Caucasian population.</s></p><p><s>The prognostic role of these findings has to be investigated in more detail in further adequately powered prospective studies.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>(1:200, Clone MIB-1, Dako1), BCL2 (1:25, clone 124, Dako1), HIF1A (1:100, Clone Halpha111a, BioZol1); K5005 Dako1 for CDX2 (1:600, clone CDX2-88, Biogenex1), CD3 (1:100, clone LN10, Novocastra1) TP53 (1:100, clone DO-7, Dako1), TP21 (1:10, clone DCS-60.2,</s><s>Thermo Scientific1), BAX (1:500, Clone A3533, Dako1, Cyclin E (1:100, clone HE12, Invitrogen1), Survivin (1:200, clone 12C4, Dako1), SSH (1:500, clone EP1190Y, Dako1</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 1 .</head><label>1</label><figDesc><div><p><s>Fig 1. Kaplan-Meier estimates of tumor related survival measured from the date of first admission stratified by vein invasion status V0 (red) /V1 (blue) (left panel) and poorly differentiated medullary cancer (PMC) (blue) vs. other histopathological subtypes (no-PMC) (red) (right panel).</s><s>doi:10.1371/journal.pone.0168237.g001</s></p></div></figDesc><graphic coords="6,48.01,77.85,528.02,287.66" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig 2 .</head><label>2</label><figDesc><div><p><s>Fig 2. Immunhistochemical and H&amp;E staining of the TMA of gastric cancer specimens (200x).</s><s>Poorly differentiated medullary cancer by H&amp;E staining (A) and CD3 staining (B).</s><s>TP53 mutated (C) and wildtype (D) tumor sample.</s><s>doi:10.1371/journal.pone.0168237.g002</s></p></div></figDesc><graphic coords="8,48.01,183.28,528.02,484.34" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Patient characteristics collected from the patient management software and the regional population-based cancer registry (n = 129). Pts. (%) Tumor related Survival (%) Overall survival (%) 5-year 10-year Log Rank 5-year 10-year Log Rank Sex</head><label>1</label><figDesc></figDesc><table><row><cell>Female</cell><cell>48 (37.2%)</cell><cell>95.8</cell><cell>93.0</cell><cell>0.713</cell><cell>91.6</cell><cell>74.8</cell><cell>0.569</cell></row><row><cell>Male</cell><cell>81 (62.8%)</cell><cell>94.7</cell><cell>91.0</cell><cell></cell><cell>79.0</cell><cell>69.7</cell><cell></cell></row><row><cell>Tumor size</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T1</cell><cell>88 (68.2%)</cell><cell>95.4</cell><cell>95.4</cell><cell>0.153</cell><cell>86.7</cell><cell>77.5</cell><cell>0.225</cell></row><row><cell>T2</cell><cell>41 (31.8%)</cell><cell>94.8</cell><cell>85.6</cell><cell></cell><cell>79.3</cell><cell>61.6</cell><cell></cell></row><row><cell>Tumor Location</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>AEG</cell><cell>33 (25.6%)</cell><cell>90.5</cell><cell>85.2</cell><cell>0.519</cell><cell>81.8</cell><cell>71.1</cell><cell>0.266</cell></row><row><cell>S 1/3</cell><cell>2 (1.6%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>50.0</cell><cell>50.0</cell><cell></cell></row><row><cell>S 2/3</cell><cell>26 (20.2%)</cell><cell>100</cell><cell>94.4</cell><cell></cell><cell>92.3</cell><cell>87.2</cell><cell></cell></row><row><cell>S 3/3</cell><cell>55 (42.6%)</cell><cell>94.3</cell><cell>92.6</cell><cell></cell><cell>87.1</cell><cell>75.5</cell><cell></cell></row><row><cell>S total</cell><cell>8 (6.2%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>100</cell><cell>100</cell><cell></cell></row><row><cell>Unspecified</cell><cell>5 (3.9%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell cols="2">Lymphatic Vessel Invasion</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>L0</cell><cell>66 (51.2%)</cell><cell>93.5</cell><cell>88.3</cell><cell>0.369</cell><cell>78.4</cell><cell>65.1</cell><cell>0.971</cell></row><row><cell>L1</cell><cell>14 (10.9%)</cell><cell>80.0</cell><cell>80.0</cell><cell></cell><cell>75.0</cell><cell>60.0</cell><cell></cell></row><row><cell>Unspecified</cell><cell>49 (38.0%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Vein Invasion</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>V0</cell><cell>63(48.8%)</cell><cell>96.7</cell><cell>91.3</cell><cell>0.005</cell><cell>85.9</cell><cell>71.3</cell><cell>0.165</cell></row><row><cell>V1</cell><cell>8 (6.2%)</cell><cell>60.0</cell><cell>60.0</cell><cell></cell><cell>42.9</cell><cell>42.9</cell><cell></cell></row><row><cell>Unspecified</cell><cell>58(45.0%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Grading</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>G1</cell><cell>12 (9.3%)</cell><cell>100</cell><cell>100</cell><cell>0.495</cell><cell>100.0</cell><cell>83.3</cell><cell>0.937</cell></row><row><cell>G2</cell><cell>42 (32.6%)</cell><cell>92.7</cell><cell>86.5</cell><cell></cell><cell>82.1</cell><cell>65.4</cell><cell></cell></row><row><cell>G3</cell><cell>71 (55%)</cell><cell>95.5</cell><cell>93.5</cell><cell></cell><cell>80.9</cell><cell>70.9</cell><cell></cell></row><row><cell>G4</cell><cell>1 (0.8%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>0.0</cell><cell>0.0</cell><cell></cell></row><row><cell>Unspecified</cell><cell>3 (2.3%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Resection</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>R0</cell><cell>98 (76.0%)</cell><cell>94.6</cell><cell>89.8</cell><cell>&lt;0.001</cell><cell>82.2</cell><cell>68.0</cell><cell>0.001</cell></row><row><cell>R1</cell><cell>1 (0.8%)</cell><cell>0.0</cell><cell>0.0</cell><cell></cell><cell>0.0</cell><cell>0.0</cell><cell></cell></row><row><cell>Unspecified</cell><cell>30 (23.3%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell cols="2">Lymph node Resection</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>D2</cell><cell>126 (97.6%)</cell><cell>94.7</cell><cell>91.7</cell><cell>0.758</cell><cell>88.7</cell><cell>78.3</cell><cell>0.473</cell></row><row><cell>D1</cell><cell>2 (1.6%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>50.0</cell><cell>50.0</cell><cell></cell></row><row><cell>Unspecified</cell><cell>1 (0.8%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell cols="2">Lauren Classification</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Intestinal</cell><cell>46 (35.7%)</cell><cell>93.3</cell><cell>90.5</cell><cell>0.533</cell><cell>82.0</cell><cell>64.0</cell><cell>0.721</cell></row><row><cell>Diffuse</cell><cell>36 (27.9%)</cell><cell>91.4</cell><cell>87.3</cell><cell></cell><cell>81.5</cell><cell>72.4</cell><cell></cell></row><row><cell>Mixed</cell><cell>11 (8.5%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>75.0</cell><cell>62.5</cell><cell></cell></row><row><cell>Unspecified</cell><cell>36 (27.9%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Relapse</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>9 (7%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>33.3</cell><cell>0.0</cell><cell>&lt;0.0001</cell></row><row><cell>No</cell><cell>120 (93%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>89.2</cell><cell>79.7</cell><cell></cell></row><row><cell>Total</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>129 (100%)</cell><cell>95.1</cell><cell>91.8</cell><cell>-</cell><cell>83.9</cell><cell>71.4</cell><cell>-</cell></row></table><note><p><s>doi:10.1371/journal.pone.0168237.t001</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 . Histopathological characteristics of the 80 tumor samples reevaluated from available formalin-fixed paraffin-embedded tissue samples.</head><label>2</label><figDesc><div><p><s>PMC: Poorly differentiated medullary cancer.</s></p></div></figDesc><table><row><cell></cell><cell>Pts. (%)</cell><cell></cell><cell cols="2">Tumor related Survival (%)</cell><cell></cell><cell cols="2">Overall survival (%)</cell></row><row><cell></cell><cell></cell><cell>5-year</cell><cell>10-year</cell><cell>Log Rank</cell><cell>5-year</cell><cell>10-year</cell><cell>Log Rank</cell></row><row><cell>Tumor size</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>T1a</cell><cell>31 (38.8%)</cell><cell>93.4</cell><cell>93.4</cell><cell>0.952</cell><cell>88.9</cell><cell>88.9</cell><cell>0.179</cell></row><row><cell>T1b</cell><cell>26 (32.5%)</cell><cell>100.0</cell><cell>90.5</cell><cell></cell><cell>94.4</cell><cell>88.9</cell><cell></cell></row><row><cell>T2</cell><cell>23 (28.8%)</cell><cell>90.6</cell><cell>90.6</cell><cell></cell><cell>73.7</cell><cell>67.5</cell><cell></cell></row><row><cell>Vein Invasion</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>V0</cell><cell>73 (91.3%)</cell><cell>98.6</cell><cell>95.0</cell><cell>&lt;0.001</cell><cell>92.1</cell><cell>85.9</cell><cell>0.001</cell></row><row><cell>V1</cell><cell>7 (8.8%)</cell><cell>53.6</cell><cell>53.6</cell><cell></cell><cell>42.9</cell><cell>42.9</cell><cell></cell></row><row><cell>Lymphatic Vessel Invasion</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>L0</cell><cell>66 (82.5%)</cell><cell>96.8</cell><cell>92.6</cell><cell>0.294</cell><cell>89.3</cell><cell>82.3</cell><cell>0.672</cell></row><row><cell>L1</cell><cell>14 (17.5%)</cell><cell>85.1</cell><cell>85.1</cell><cell></cell><cell>78.6</cell><cell>78.6</cell><cell></cell></row><row><cell>Grading</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>G1</cell><cell>7 (8.8%)</cell><cell>100</cell><cell>100</cell><cell>0.774</cell><cell>100</cell><cell>100</cell><cell>0.589</cell></row><row><cell>G2</cell><cell>27 (33.8%)</cell><cell>96.2</cell><cell>91.6</cell><cell></cell><cell>88.8</cell><cell>83.1</cell><cell></cell></row><row><cell>G3</cell><cell>46 (57.5%)</cell><cell>93.2</cell><cell>90.5</cell><cell></cell><cell>84.9</cell><cell>78.6</cell><cell></cell></row><row><cell>Lauren Classification</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Intestinal</cell><cell>56 (70.0%)</cell><cell>92.6</cell><cell>88.0</cell><cell>0.280</cell><cell>86.2</cell><cell>80.7</cell><cell>0.282</cell></row><row><cell>Diffuse</cell><cell>13 (16.3%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>81.8</cell><cell>71.6</cell><cell></cell></row><row><cell>Mixed</cell><cell>11 (13.8%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>100</cell><cell>100</cell><cell></cell></row><row><cell>WHO Classification (modified)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Tubular</cell><cell>40(50.0%)</cell><cell>97.5</cell><cell>97.6</cell><cell>0.004</cell><cell>91.9</cell><cell>84.0</cell><cell>0.420</cell></row><row><cell>Papillary</cell><cell>3 (3.8%)</cell><cell>66.7</cell><cell>66.7</cell><cell></cell><cell>66.7</cell><cell>66.7</cell><cell></cell></row><row><cell>Mucinous</cell><cell>2 (2.5%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>50.0</cell><cell>-</cell><cell></cell></row><row><cell>PMC</cell><cell>9 (11.3%)</cell><cell>75.0</cell><cell>56.3</cell><cell></cell><cell>80.0</cell><cell>60.0</cell><cell></cell></row><row><cell>Pyloric gland type</cell><cell>4 (5.0%)</cell><cell>100</cell><cell>66.7</cell><cell></cell><cell>75.0</cell><cell>75.0</cell><cell></cell></row><row><cell>Poorly cohesive (signet ring)</cell><cell>15 (18.8%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>85.7</cell><cell>77.9</cell><cell></cell></row><row><cell>Mixed</cell><cell>7 (8.8%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>60</cell><cell>60</cell><cell></cell></row><row><cell>Ming Classification</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Expansive</cell><cell>38 (47.5%)</cell><cell>91.7</cell><cell>88.3</cell><cell>0.175</cell><cell>86.3</cell><cell>82.7</cell><cell>0.903</cell></row><row><cell>Infiltrative</cell><cell>37 (46.3%)</cell><cell>97.4</cell><cell>97.4</cell><cell></cell><cell>88.4</cell><cell>80.8</cell><cell></cell></row><row><cell>Not possible</cell><cell>5 (6.3%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Total</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>80 (100%)</cell><cell>94.8</cell><cell>91.4</cell><cell>-</cell><cell>83.9</cell><cell>71.4</cell><cell>-</cell></row><row><cell>doi:10.1371/journal.pone.0168237.t002</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p><s>(Continued) Samples &gt; 20% positive cells were evaluated as high proliferative tumors.</s><s>** TP53 Samples with 75-100% stained cells and strong nuclear staining intensity were scored as TP53 mutated.</s></p></div></figDesc><table><row><cell></cell><cell>Pts. (%)</cell><cell cols="2">Tumor related survival (%)</cell><cell></cell><cell cols="2">Overall survival (%)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>5-year</cell><cell>10-year</cell><cell>Log Rank</cell><cell>5-year</cell><cell>10-year</cell><cell>Log Rank</cell></row><row><cell>Negative</cell><cell>5 (6.3%)</cell><cell>100.0</cell><cell>100.0</cell><cell>0.466</cell><cell>100.0</cell><cell>50.0</cell><cell>0.837</cell></row><row><cell>Positive</cell><cell>63 (78.8%)</cell><cell>93.3</cell><cell>89.0</cell><cell></cell><cell>82.8</cell><cell>74.8</cell><cell></cell></row><row><cell>n.a.</cell><cell>12 (15.0%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Mismatch repair system</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Proficient</cell><cell>53 (66.3%)</cell><cell>92.1</cell><cell>87.3</cell><cell>0.461</cell><cell>82.0</cell><cell>72.0</cell><cell>0.842</cell></row><row><cell>Deficient</cell><cell>5 (6.3%)</cell><cell>100</cell><cell>100</cell><cell></cell><cell>75.0</cell><cell>75.0</cell><cell></cell></row><row><cell>n.a.</cell><cell>22 (27.5%)</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell><cell>-</cell></row><row><cell>Total</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>80 (100%)</cell><cell>94.8</cell><cell>91.4</cell><cell>-</cell><cell>83.9</cell><cell>71.4</cell><cell>-</cell></row><row><cell>*Ki-67:</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>***Survivin: tumors with &gt;5% positive stained nuclei were scored as positive.</s><s>n.a.: not assessable doi:10.1371/journal.pone.0168237.t003</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">PLOS ONE | DOI:10.1371/journal.pone.0168237December 28, 2016  </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>We thank Dr. Joachim Gerloff for the formative discussion and critical reading of the manuscript and Dr. Esmeralda Heiden for the administrative support on the tumor biobank of the Charite ´Cancer Comprehensive Center.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S1 Table. Clinical data and IHC scoring value for each marker. (XLSX)</head><p><s>Author Contributions</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I I</forename><surname>Soerjomataram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dikshit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rebelo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int. J. Cancer</title>
		<imprint>
			<biblScope unit="page">0</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Patterns of initial recurrence in completely resected gastric adenocarcinoma</title>
		<author>
			<persName><forename type="first">M</forename><surname>D'angelica</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bains</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Karpeh</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.sla.0000143245.28656.15</idno>
		<idno type="PMID">15492562</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Surg</title>
		<imprint>
			<biblScope unit="volume">240</biblScope>
			<biblScope unit="page" from="808" to="816" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Relevant prognostic factors in Gastric Cancer: ten-year results of teh German Gastric Cancer Study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Siewert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bo ¨ttcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Roder</surname></persName>
		</author>
		<idno type="PMID">9790335</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Surg</title>
		<imprint>
			<biblScope unit="volume">228</biblScope>
			<biblScope unit="page" from="449" to="461" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial</title>
		<author>
			<persName><forename type="first">I</forename><surname>Songun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Putter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Em-K</forename><surname>Kranenbarg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sasako</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cjh</forename><surname>Van De Velde</surname></persName>
		</author>
		<idno type="DOI">10.1016/S1470-2045(10)70070-X</idno>
		<idno type="PMID">20409751</idno>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="439" to="449" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers</title>
		<author>
			<persName><forename type="first">D</forename><surname>Marrelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Morgagni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>De Manzoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coniglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Saragoni</surname></persName>
		</author>
		<idno type="DOI">10.1097/SLA.0b013e3182389b1a</idno>
		<idno type="PMID">22167003</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Surg</title>
		<imprint>
			<biblScope unit="volume">255</biblScope>
			<biblScope unit="page" from="486" to="491" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Siewert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bo ¨ttcher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Roder</surname></persName>
		</author>
		<idno type="PMID">9790335</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Surg</title>
		<imprint>
			<biblScope unit="volume">228</biblScope>
			<biblScope unit="page" from="449" to="461" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Ho ¨lscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Drebber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Mo ¨nig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schulte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Vallbo ¨hmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bollschweiler</surname></persName>
		</author>
		<idno type="DOI">10.1097/SLA.0b013e3181bdd3e4</idno>
		<idno type="PMID">19809298</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Surg</title>
		<imprint>
			<biblScope unit="volume">250</biblScope>
			<biblScope unit="page" from="791" to="797" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Prognostic factors for early gastric cancer in France: Cox regression analysis of 332 cases</title>
		<author>
			<persName><forename type="first">F</forename><surname>Borie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Rigau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Fingerhut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Millat</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00268-004-7127-8</idno>
		<idno type="PMID">15383869</idno>
	</analytic>
	<monogr>
		<title level="j">World J. Surg</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="686" to="691" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic value</title>
		<author>
			<persName><forename type="first">F</forename><surname>Berlth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bollschweiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Drebber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Hoelscher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Moenig</surname></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v20.i19.5679</idno>
		<idno type="PMID">24914328</idno>
	</analytic>
	<monogr>
		<title level="j">World J. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="5679" to="5684" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Prognostic factors of advanced gastric carcinoma without serosal invasion (pT2 gastric carcinoma)</title>
		<author>
			<persName><forename type="first">H</forename><surname>Isozaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fujii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Nomura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mabuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Nishiguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hara</surname></persName>
		</author>
		<idno type="PMID">10522062</idno>
	</analytic>
	<monogr>
		<title level="j">Hepatogastroenterology</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="2669" to="2672" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Prediction of risk factors for lymph node metastasis in early gastric cancer</title>
		<author>
			<persName><forename type="first">G</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W-J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-M</forename><surname>Ou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Y-N</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W-H</forename></persName>
		</author>
		<idno type="DOI">10.3748/wjg.v19.i20.3096</idno>
		<idno type="PMID">23716990</idno>
	</analytic>
	<monogr>
		<title level="j">World J. Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="3096" to="3107" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Long-term survival results and prognostic factors of early gastric cancer</title>
		<author>
			<persName><forename type="first">B</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.3892/etm.2011.323</idno>
		<idno type="PMID">22977620</idno>
	</analytic>
	<monogr>
		<title level="j">Exp. Ther. Med</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1059" to="1064" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Prognostic factors in gastric cancer with serosal invasion. Univariate and multivariate analyses</title>
		<author>
			<persName><forename type="first">H</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Korenaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Okamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sugimachi</surname></persName>
		</author>
		<idno type="PMID">2774908</idno>
	</analytic>
	<monogr>
		<title level="j">Arch. Surg</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="page" from="1061" to="1064" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Evaluation of 530 patients. New elements for an updated definition and classification</title>
		<author>
			<persName><forename type="first">L</forename><surname>Saragoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Morgagni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Marfisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Vittimberga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Garcea</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10120-013-0233-2</idno>
		<idno type="PMID">23423491</idno>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="549" to="554" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Early gastric cancer: diagnosis, staging, and clinical impact</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Clinicopathological and prognostic significance of Ki-67, caspase-3 and p53 expression in gastric carcinomas</title>
		<author>
			<persName><forename type="first">H-C</forename><surname>Zheng</surname></persName>
		</author>
		<idno type="DOI">10.3892/ol.2013.1532</idno>
		<idno type="PMID">24179508</idno>
	</analytic>
	<monogr>
		<title level="j">Oncol. Lett</title>
		<imprint>
			<biblScope unit="page" from="1277" to="1284" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Role of cyclin E and p53 expression in progression of early gastric cancer</title>
		<author>
			<persName><forename type="first">L</forename><surname>Jiaqing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hokita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xiangming</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Natsugoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tanabe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baba</surname></persName>
		</author>
		<idno type="DOI">10.1007/s101209800010</idno>
		<idno type="PMID">11957061</idno>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="160" to="165" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Combined evaluation of expressions of p53 and p21 proteins as prognostic factors for patients with gastric carcinoma</title>
		<author>
			<persName><forename type="first">T</forename><surname>Okuyama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Maehara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kabashima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kakeji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sugimachi</surname></persName>
		</author>
		<idno type="PMID">12417790</idno>
	</analytic>
	<monogr>
		<title level="j">Oncology</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="353" to="361" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Molecular-pathological prognostic factors of gastric cancer: a review</title>
		<author>
			<persName><forename type="first">W</forename><surname>Yasui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Oue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Aung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Matsumura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shutoh</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10120-005-0320-0</idno>
		<idno type="PMID">15864715</idno>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="page" from="86" to="94" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma?</title>
		<author>
			<persName><forename type="first">G</forename><surname>Kouraklis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Katsoulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Theocharis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tsourouflis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Xipolitas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Glinavou</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10620-008-0464-y</idno>
		<idno type="PMID">19058005</idno>
	</analytic>
	<monogr>
		<title level="j">Dig. Dis. Sci</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="1015" to="1020" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Prognostic significance of p53 in gastric cancer: a meta-analysis. Asian Pac</title>
		<author>
			<persName><forename type="first">M</forename><surname>Yildirim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Demirpence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gunduz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bozcuk</surname></persName>
		</author>
		<idno type="PMID">25640374</idno>
	</analytic>
	<monogr>
		<title level="j">J. Cancer Prev</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="327" to="332" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Combined p53/Bax mutation results in extremely poor prognosis in gastric carcinoma with low microsatellite instability</title>
		<author>
			<persName><forename type="first">A</forename><surname>Mrozek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Petrowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sturm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Death</title>
		<imprint>
			<biblScope unit="page" from="461" to="467" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Prediction of tumor recurrence after curative resection in gastric carcinoma based on bcl-2 expression</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Cai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1186/1477-7819-12-40</idno>
		<idno type="PMID">24555747</idno>
	</analytic>
	<monogr>
		<title level="j">World J. Surg. Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">40</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Role of survivin as prognostic and clinicopathological marker in gastric cancer: a meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Krieg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Baseras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tomczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Verde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Stoecklein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">T</forename><surname>Knoefel</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11033-013-2650-z</idno>
		<idno type="PMID">23948878</idno>
	</analytic>
	<monogr>
		<title level="j">Mol. Biol. Rep</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="5501" to="5511" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer</title>
		<author>
			<persName><forename type="first">D</forename><surname>Vallbo ¨hmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kuhn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Warnecke-Eberz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brabender</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Metzger</surname></persName>
		</author>
		<idno type="DOI">10.2217/14622416.9.6.681</idno>
		<idno type="PMID">18518847</idno>
	</analytic>
	<monogr>
		<title level="j">Pharmacogenomics</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="681" to="690" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk</title>
		<author>
			<persName><forename type="first">E</forename><surname>Liarmakopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Theodoropoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vaiopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rizos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Aravantinos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kouraklis</surname></persName>
		</author>
		<idno type="DOI">10.3892/mmr.2012.1247</idno>
		<idno type="PMID">23258739</idno>
	</analytic>
	<monogr>
		<title level="j">Mol. Med. Rep</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="887" to="892" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">S</forename><surname>Warneke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H-M</forename><surname>Behrens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Haag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Balschun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bo ¨ger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Becker</surname></persName>
		</author>
		<idno type="DOI">10.1097/PDM.0b013e318284188e</idno>
		<idno type="PMID">23846438</idno>
	</analytic>
	<monogr>
		<title level="j">Diagn. Mol. Pathol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="127" to="137" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">The Significances of Lymph Node Micrometastasis and its Correlation With E-Cadherin Expression in pT1-T3N0 Gastric Adenocarcinoma</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<idno type="DOI">10.1002/jso.20937</idno>
		<idno type="PMID">18095267</idno>
	</analytic>
	<monogr>
		<title level="j">J. Surg. Oncol</title>
		<imprint>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gamboa-Dominguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Seidl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Reyes-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hermannsta ¨dter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Quintanilla-Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Busch</surname></persName>
		</author>
		<idno type="DOI">10.1136/jcp.2006.038976</idno>
		<idno type="PMID">17483253</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Pathol</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="756" to="761" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Homeoprotein Cdx2 and nuclear PTEN expression profiles are related to gastric cancer prognosis</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Cui</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1600-0463.2007.00654.x</idno>
		<idno type="PMID">18184409</idno>
	</analytic>
	<monogr>
		<title level="j">APMIS</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="1383" to="1390" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clinicopathological correlation and prognostic significance of protein kinase cα overexpression in human gastric carcinoma</title>
		<author>
			<persName><forename type="first">S-C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W-Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K-Y</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C-C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S-E</forename><surname>Lin</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0056675</idno>
		<idno type="PMID">23468872</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e56675</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">TROP2 expression as prognostic marker for gastric carcinoma</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mu ¨hlmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Spizzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gostner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Maier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Moser</surname></persName>
		</author>
		<idno type="DOI">10.1136/jcp.2008.060590</idno>
		<idno type="PMID">18930986</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Pathol</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="152" to="158" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Overexpression of hypoxia-inducible factor 1 α and p53 is a marker for an unfavorable prognosis in gastric cancer</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sumiyoshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kakeji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Egashira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mizokami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Orita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Maehara</surname></persName>
		</author>
		<idno type="DOI">10.1158/1078-0432.CCR-05-2382</idno>
		<idno type="PMID">16951228</idno>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="5112" to="5117" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qu</surname></persName>
		</author>
		<idno type="DOI">10.3892/mco.2015.506</idno>
		<idno type="PMID">26137290</idno>
	</analytic>
	<monogr>
		<title level="j">Mol. Clin. Oncol</title>
		<imprint>
			<biblScope unit="page" from="699" to="705" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<monogr>
		<title level="m" type="main">World Health Organization Classification of Tumours Pathology and Genetics of Digestive System</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Hamilton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Aaltonen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Poorly differentiated medullary carcinoma of the stomach</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Adachi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Maehara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sugimachi</surname></persName>
		</author>
		<idno type="PMID">1515997</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1462" to="1466" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">High incidence of liver metastasis in gastric cancer with medullary growth pattern</title>
		<author>
			<persName><forename type="first">N</forename><surname>Kaibara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Kimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nishidoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Makino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kawasumi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Koga</surname></persName>
		</author>
		<idno type="PMID">3974246</idno>
	</analytic>
	<monogr>
		<title level="j">J. Surg. Oncol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="195" to="198" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma</title>
		<author>
			<persName><forename type="first">P</forename><surname>Grabowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ku ¨hnel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mu ¨hr-Wilkenshoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Heine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Stein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ho ¨pfner</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.bjc.6600696</idno>
		<idno type="PMID">12556969</idno>
	</analytic>
	<monogr>
		<title level="j">Br. J. Cancer</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="page" from="115" to="119" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Yemelyanova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kshirsagar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><surname>Marks M A</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Shih</surname></persName>
		</author>
		<idno type="DOI">10.1038/modpathol.2011.85</idno>
		<idno type="PMID">21552211</idno>
	</analytic>
	<monogr>
		<title level="j">Mod. Pathol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="1248" to="1253" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">TP53 and gastric carcinoma: A review</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Fenoglio-Preiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Stemmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Noffsinger</surname></persName>
		</author>
		<idno type="DOI">10.1002/humu.10180</idno>
		<idno type="PMID">12619111</idno>
	</analytic>
	<monogr>
		<title level="j">Hum. Mutat</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="258" to="270" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">REporting recommendations for tumor MARKer prognostic studies (REMARK)</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mcshane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sauerbrei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Taube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gion</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Clark</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10549-006-9242-8</idno>
		<idno type="PMID">16932852</idno>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res. Treat</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="229" to="235" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Importance of events per independent variable in proportional hazards regression analysis II. Accuracy and precision of regression estimates</title>
		<author>
			<persName><forename type="first">P</forename><surname>Peduzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Concato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Feinstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Holford</surname></persName>
		</author>
		<idno type="PMID">8543964</idno>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Epidemiol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="1503" to="1510" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Cancer incidence and mortality worldwide: IARC CancerBase No</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ferlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Soerjomataram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ervik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dikshit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mathers</surname></persName>
		</author>
		<idno>v1. 0</idno>
	</analytic>
	<monogr>
		<title level="s">Available from globocan. iarc. fr</title>
		<imprint>
			<biblScope unit="issue">11</biblScope>
			<date type="published" when="2012">2012. 2013. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">External Validation of an Eastern Asian Nomogram for Survival Prediction After Gastric Cancer Surgery in a European Patient Cohort</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Iij</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Recurrence after curative resection of early gastric cancer</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Youn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>An</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Noh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Sohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<idno type="DOI">10.1245/s10434-009-0772-2</idno>
		<idno type="PMID">19904573</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. Surg. Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="448" to="454" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Systematic review of enhanced recovery after gastro-oesophageal cancer surgery</title>
		<author>
			<persName><forename type="first">E</forename><surname>Gemmill</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Humes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Catton</surname></persName>
		</author>
		<idno type="DOI">10.1308/003588414X14055925061630</idno>
		<idno type="PMID">26263799</idno>
	</analytic>
	<monogr>
		<title level="j">Ann. R. Coll. Surg. Engl</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="173" to="179" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Comprehensive molecular characterization of gastric adenocarcinoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Thorsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Shmulevich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bernard</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature13480</idno>
		<idno type="PMID">25079317</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">513</biblScope>
			<biblScope unit="page" from="202" to="209" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer</title>
		<author>
			<persName><forename type="first">N</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med. Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Protein expression status in mucosal and submucosal portions of early gastric cancers and their predictive value for lymph node metastasis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Choe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H-H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<idno type="DOI">10.1111/apm.12119</idno>
		<idno type="PMID">23758612</idno>
	</analytic>
	<monogr>
		<title level="j">APMIS</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="926" to="937" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Role of p53 in the progression of gastric cancer</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Busuttil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G V</forename><surname>Zapparoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haupt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fennell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Pang</surname></persName>
		</author>
		<idno type="DOI">10.18632/oncotarget.2434</idno>
		<idno type="PMID">25427447</idno>
	</analytic>
	<monogr>
		<title level="j">Oncotarget</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="12016" to="12026" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes</title>
		<author>
			<persName><forename type="first">R</forename><surname>Cristescu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nebozhyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K-M</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Ting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<date type="published" when="2015">2015;21</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Simbolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mafficini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pilotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Capelli</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10120-013-0315-1</idno>
		<idno type="PMID">24272205</idno>
	</analytic>
	<monogr>
		<title level="j">Gastric Cancer</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="442" to="449" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
